Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
11 evidence topics · 13 sources
Summary
COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.
VA/DoD guideline: recommendation against psilocybin outside a research setting
CANMAT 2023 update: psilocybin-assisted psychotherapy considered investigational
“Psychedelic-assisted psychotherapy was recently reviewed in a CANMAT Task Force Report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although these results are promising, they are limited by ongoing methodological issues (e.g., lack of blinding, inadequate assessment of expectancy bias, heterogeneity of psychological support, and lack of long-term safety data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, psilocybin- and other psychedelic-assisted psychotherapies are considered investigational treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT task force: psilocybin an experimental treatment for use within clinical trials
“There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EMA depression guideline: psychedelic development in treatment-resistant depression and a controlled environment
NICE guideline recommendations for treatment-resistant depression
ICER assessment scope: population, intervention, comparators, and setting
Company statements on intended position in treatment-resistant depression
Anticipated dosing pattern: one or two initial administrations, then episodic retreatment
Anticipated care setting: certified interventional psychiatry treatment centers
Payer panel perspectives on the place of psilocybin in therapy
“Perspectives among participants on the current evidence for psilocybin in TRD were mixed, with some indicating it is compelling or promising and their organization would likely cover upon FDA approval and others indicating it is uncertain or insufficient and would likely adopt a wait-and-see approach to coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These participants cited the lack of clinical treatment guidelines, comparative studies, and cost-effectiveness data as particular challenges when trying to determine the place in therapy of a new treatment and make coverage decisions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants indicated that the most important evidence required to support coverage of psilocybin would be head-to-head trials vs esketamine or other active comparators such as SGAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote